Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

Allergy Therapeutics to present on Investor Meet Company platform

29 September 2022 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, is pleased to announce that Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore, Head of Business Innovation, will provide a live presentation relating to the Group's recently announced Unaudited Preliminary Results for the Year ended 30 June 2022 on the Investor Meet Company platform on Monday 3 October 2022 at 10:00am BST.

The presentation, which is open to all existing and potential shareholders, will be followed by a Q&A session. Questions can be submitted ahead of the event through the Investor Meet Company dashboard up until 9:00am the day before the meeting, or at any time during the live presentation.

To sign up to Investor Meet Company for free, and to register for the Group's presentation, please visit: https://www.investormeetcompany.com/allergy-therapeutics-plc/register-investor

Those already following Allergy Therapeutics PLC on the Investor Meet Company platform will automatically be invited to the event.

- ENDS -

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon (Nominated Adviser and Broker)

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

[email protected]

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

[email protected]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which employs c.600 employees, is listed on the London Stock Exchange (AIM: AGY). For more information, please see www.allergytherapeutics.com.